| Autor: |
Ashrafi Jigheh, Zahra, Ghorbani Haghjo, Amir, Argani, Hassan, Roshangar, Leila, Rashtchizadeh, Nadereh, Sanajou, Davoud, Nazari Soltan Ahmad, Saeed, Rashedi, Jalil, Dastmalchi, Siavoush, Mesgari Abbasi, Mehran |
| Zdroj: |
Indian Journal of Clinical Biochemistry; Jan2020, Vol. 35 Issue 1, p109-114, 6p |
| Abstrakt: |
Empagliflozin, a SGLT-2 inhibitor, improves diabetic nephropathy through its pleiotropic anti-inflammatory effects. The present study aims to evaluate empagliflozin effects on renal and urinary levels of tubular epithelial cell injury markers in streptozotocin-induced diabetic rats. Empagliflozin at 10 mg/kg (p.o.) was administered for 4 weeks, beginning 8 weeks after induction of diabetes. Renal function as well as markers of renal tubular epithelial cell injury were assessed in kidney tissue homogenates and urine. Empagliflozin was able to ameliorate diabetes induced elevations in serum cystatin C levels. It also alleviated renal KIM-1/NGAL levels and urinary albumin, α-GST, and RBP excretions. In addition to decreasing urinary levels of cell cycle arrest indices i.e. TIMP-2 and IGFBP7, empagliflozin mitigated acetylated NF-κB levels in renal tissues of diabetic rats. As a whole, these findings reveal empagliflozin capability in improving diabetic nephropathy via ameliorating indices of renal inflammation, injury, and cell cycle arrest on streptozotocin-induced diabetic rats. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink